Victory Capital Management
IMUX icon

Victory Capital Management’s Immunic IMUX Stock Holding History

Victory Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-140
Closed -$8K – 2861
2020
Q1 		$8K Buy
+140
New +$11.3K ﹤0.01% 3154
2019
Q4 		– Sell
-173
Closed -$17K – 2927
2019
Q3 		$17K Buy
+173
New +$23.2K ﹤0.01% 3098
2018
Q3 		– Sell
-7,693
Closed -$21.1M – 1832
2018
Q2 		$21.1M Buy
7,693
+229
+3% +$529K 0.04% 585
2018
Q1 		$20.3M Buy
7,464
+149
+2% +$342K 0.04% 581
2017
Q4 		$17.4M Buy
7,315
+807
+12% +$1.78M 0.04% 611
2017
Q3 		$13.1M Buy
6,508
+60
+0.9% +$78.3K 0.03% 674
2017
Q2 		$7.48M Buy
6,448
+74
+1% +$98.8K 0.02% 751
2017
Q1 		$10.2M Buy
6,374
+557
+10% +$1.02M 0.02% 690
2016
Q4 		$10.1M Buy
5,817
+11
+0.2% +$24.1K 0.03% 680
2016
Q3 		$14.2M Buy
+5,806
New +$14.3M 0.04% 634

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Victory Capital Management's IMUX Position: Q2 2020 in Review

Victory Capital Management sold out of Immunic (IMUX) in Q2 2020, closing a stake of 140 shares — an estimated $8K sold.

Victory Capital Management first reported a position in IMUX in Q3 2016 and held it in 10 quarters. The position peaked at $21.1M in Q2 2018. 51 funds tracked by Wall St. Rank hold IMUX as of Q2 2020.

  • Victory Capital Management reported no remaining Immunic position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 140 Immunic shares in Q2 2020, an estimated $8K.
  • Victory Capital Management first reported a position in Immunic in Q3 2016 and held it in 10 quarters.
  • Victory Capital Management's Immunic position peaked at $21.1M in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Immunic as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.